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of novel cancer drugs approved over the past 11 years are used with a curative
intent or provide a survival benefit in the palliative care setting. However, the
monthly cost for agents not providing these benefits was higher, indicating a dis-
connect between efficacy and cost.
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OBJECTIVES:To predict the potential cost and effects of addingmaleswith females
for HPV vaccination in Thailand. Human Papillomavirus (HPV) is the most com-
monly sexual transmitted virus in the United States. The American Academy of
Pediatrics (AAP) recommends HPV vaccination for adolescent. Many studies show
that HPV vaccination is beneficial in preventing HPV-associated diseases, such as
cervical cancers, cervical intraepithelial neoplasia (CIN), genital warts and others.
In Thailand, cervical cancer is the second most common cancer. The cost and
effects of vaccination in males is generally considered as beneficial as vaccine
coverage of females.METHODS: A basic model of HPV vaccination was developed
based on current literatures to estimate the economic and health effects of HPV-
associated diseases in both males and females in the United States comparing to
populations in Thailand. RESULTS: The baseline vaccination costs per case in USA
and Thailand are 500 USD and 265 USD (9283 baht) respectively. The QALYs gained
per case for both countries are 0.0126 in females and 0.0094 for combined males
and females. Totals for combinedmales and females vaccination is 493,153 QALYs
for USA and 13,957 QALYs for Thailand.CONCLUSIONS:Adding HPV vaccination in
adolescent males in Thailand is certainly more costly, but still beneficial. The po-
tential of health benefits depends more on the female HPV vaccination coverage,
however,males add benefits also. If the coverage rate for females is high, the health
benefits increase. Based on the total population, the benefits can be substantial.
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OBJECTIVES: To assess the cost-effectiveness of introducing CT colonography
(CTC) into the colorectal cancer (CRC) screening program in Japan. METHODS: A
Markovmodel for CRCwas constructed to estimate both the short-term (one-1year)
and the long-term (10-year, 20-year, and lifetime) impact of CTC on costs and
health outcomes using three strategies. Strategy-1was the current screening strat-
egy in Japan, which consists of fecal occult blood test (FOBT) and occult-colonos-
copy (OC). In Strategy-2 and Strategy-3, CTC was added between FOBT and OC. In
Strategy-2, those who were showed positive in FOBT were asked to take CTC (up-
take81.6%). In Strategy-3, only those who rejected OC (36.8%) were asked to take
CTC (uptake50%). ICERs for Strategy-2 and Strategy-3 against Strategy-1 were
calculated. Epidemiological data was obtained mainly from statistics published by
Japanese National Cancer Center. Annual discount rate for both costs and out-
comeswas set as 3%. One-way sensitivities analysis was performed. RESULTS: The
introduction of CTC into the CRC screening program in Japan was proposed to
improve the program effect. For the short-term impact, ICERs for additional CRC
detection were JPY 2,202,000 (1USD80JPY) in Strategy-2 and JPY672,000 in Strate-
gy-3, respectively. For the long-term impact, in the base-case analysis, ICERs for
additional colorectal cancer death avoided were JPY39,660,000 in Strategy-2 and
JPY2,465,000 in Strategy-3, respectively. ICERs for life-year gained were
JPY7,804,000 in Strategy-2 and JPY484,000 in Strategy-3, respectively. During esti-
mating the total lifetime impact, Strategy-3 was considered more cost saving than
Strategy-1. CONCLUSIONS: Although this study did not include the concept of
QALY, the results suggested that CTC may be likely to improve the CRC screening
program in Japan with reasonable costs. Early detection of CRC would improve
patients’ quality of life; moreover, in a long-term perspective, increased costs for
screening may be compensated for decreased costs when treating patients with
advanced CRC.
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OBJECTIVES: To estimate the cost- effectiveness of temsirolimus as a treatment
option in poor risk renal cell carcinoma compared with interferon- and from the
perspective of national health insurance in Taiwan.METHODS:Adecision-analytic
model was developed to estimate the cost effectiveness of temsirolimus. Cost and
the clinical effectiveness data were obtained from published literature and current
reimbursed price published by Bureau of National Health Insurance. All costs and
outcomes were discounted at an annual rate of 3%. The effect of parameter uncer-
tainty on cost-effectiveness was explored through extensive one-way and proba-
bilistic sensitivity analyses. RESULTS: Compared with interferon-a, temsirolimus
treatment resulted in an discounted incremental cost per QALY gained of NT$
4,775,609, based on an estimated mean gain of 0.24 quality- adjusted life years
(QALYs) per patient; and a cost per life-year gain of NT$ 2,512,048. Cost-effective-
ness estimates were most sensitive to changes in hazard ratios for overall survival
between temsirolimus and interferon-a.CONCLUSIONS: In comparisonwith inter-
feron-a, the ICER (NT$4,775,609) for temsirolimus as a treatment in poor risk renal
cell carcinoma, was found to be much higher than the threshold suggested by the
World Health Organization. Therefore, temsirolimus could not be regarded as a
cost-effective option from the National Health Insurance perspective.
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OBJECTIVES: The worldwide incidence of melanoma is increasing rapidly. Two
chemotherapy regimens are used for treatment of Malignant Melanoma: single
agent intravenous Dacarbazine (DTIC) and oral Temozolomide (TMZ). TMZ has
greater cost in Iran so we aimed to do an economic evaluation, to evaluate the
comparative value of treatment of two drugs.METHODS: To compare the efficacy
of these two drugs, a systematic review and meta-analysis were conducted and
published articles, comparing use of single agent Dacarbazine and Temozolomide
in treatment of Malignant Melanoma were reviewed. For this purpose, Pubmed,
Scopous, Web of Science and Cochrane Central Register of Controlled Trials were
searched and the search termswere: “Dacarbazine” and “Temozolomide” and “Ma-
lignantMelanoma”. Datawere collected from inception to 2012. “Response to treat-
ment” includes:” complete response (CR)”,” partial response (PR)” and “stable dis-
ease (SD)”was the key outcomeof interest. The direct cost (drug and administrative
procedures costs) was collected from health provider centers. RESULTS: Themeta-
analysis included 3 RCTS and involved 1314 patients with malignant melanoma.
Approximately half of them were allocated to the TMZ arm and half to the DTIC
arm. Risk differences for CR was -0.01, for PR was 0.03 and for SD was 0.01.
Average cost for one cycle of treatment with TMZ is $1957 and for DTIC is $90 in
Iran. For CR based on economic evaluation grid, TMZ treatment is dominated. The
incremental CE ratio for PR is $62,233 and ICER for SD is $186,700 respectively.
CONCLUSIONS: Considering health outcomes of CR, PR and SD, Temozolomide
treatment for melanoma is not cost effective comparing to Dacarbazine in Iran. It
should be mentioned that generic Dacarbazine is available in Iran but Temozolo-
mide is provided as branded, and availability to generic form of Temozolomide
may affect the results of this economic evaluations.
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OBJECTIVES: To compare the effectiveness and cost-effectiveness of erlotinib ver-
sus gefitinib in first-line treatment of epidermal growth factor receptor (EGFR) ac-
tivating-mutation positive (MuT) non-small cell lung cancer (NSCLC) for Hong
Kong. METHODS: An indirect treatment comparison (ITC), using the Bucher et al
methodology, and a cost-effectiveness assessment (CEA) were performed on the
basis of Asian phase-III randomized controlled trials (RCTs). In total four RCTswere
determined: one for erlotinib (OPTIMAL) and three for gefitinib (IPASS; NEGJSJ,
WJTOG). The CEA model uses a Markov approach that simulates the transition
between the health states: progression-free-survival (PFS), progression and death,
inmonthly cycles over a life-timehorizon. TheWorldHealthOrganization criterion
(incremental cost-effectiveness ratio  3 times GDP/capita; USD 102,582;
,HKD	798,078)was used to rate cost-effectiveness.RESULTS:The best fit of study
characteristics and of prognostic patient characteristics were found between the
OPTIMAL and IPASS trials. Comparing the PFS hazard ratios (HRs) of erlotinib vs.
gefitinib using only these RCTs in an ITC resulted in a statistically significant PFS
difference in favor of erlotinib (ITC HR: 0.33; 95% confidence-intervals: 0.19-0.58;
p0.0001). The CEA model obtained an additional benefit of 0.36 progression-free
life years gained and of 0.23 quality-adjusted life years gained (QALYs) by erlotinib,
whichwas accompanied by additional costs of USD 14,061 (HKD	109,395). The cost
per progression-free life year gained and per QALY gained were USD 39,431
(HKD	306,773) and USD 62,419 (HKD	485,619) comparing erlotinib vs. gefitinib,
respectively.CONCLUSIONS:The ITC of OPTIMAL and IPASS shows that erlotinib is
more efficacious when compared to gefitinib. The CEA for Hong Kong shows that
the costs per progression-free life year gained and the cost per QALY gained by
erlotinib are well within an acceptable range in relation to the survival benefit
obtained. Erlotinib is cost-effective compared to gefitinib in first-line EGFR MuT
NSCLC.
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OBJECTIVES: This study aimed to evaluate the long-term cost-effectiveness of dif-
ferent strategies for self-sampling of human papillomavirus (HPV) testing for cer-
vical cancer screening in Taiwan. METHODS: This study adopts a perspective of
Department of Health in cost-effectiveness analysis to compare a no-screening
strategy with seven different screening strategies. The target populations who
aged over 36 years old and didn’t attend to the regular cervical cancer screening
program over 6 years. The published Markov model of cervical cancer screening in
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